Skip to main content

Peer Review reports

From: SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer

Original Submission
6 Jul 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
25 Sep 2023 Author responded Author comments - Elisha Fredman
Resubmission - Version 3
25 Sep 2023 Submitted Manuscript version 3
1 Nov 2023 Reviewed Reviewer Report
14 Feb 2024 Author responded Author comments - Elisha Fredman
Resubmission - Version 4
14 Feb 2024 Submitted Manuscript version 4
15 Feb 2024 Author responded Author comments - Elisha Fredman
Resubmission - Version 5
15 Feb 2024 Submitted Manuscript version 5
17 Mar 2024 Reviewed Reviewer Report
19 Mar 2024 Author responded Author comments - Elisha Fredman
19 Mar 2024 Reviewed Reviewer Report - Raymond Miralbell
Resubmission - Version 6
19 Mar 2024 Submitted Manuscript version 6
20 Mar 2024 Author responded Author comments - Elisha Fredman
Resubmission - Version 7
20 Mar 2024 Submitted Manuscript version 7
20 Mar 2024 Author responded Author comments - Elisha Fredman
Resubmission - Version 8
20 Mar 2024 Submitted Manuscript version 8
21 Mar 2024 Reviewed Reviewer Report - Raymond Miralbell
Resubmission - Version 9
Submitted Manuscript version 9
Publishing
21 Mar 2024 Editorially accepted
8 Apr 2024 Article published 10.1186/s12885-024-12165-1

You can find further information about peer review here.

Back to article page